Global AI signs pharmaceutical deal to automate regulatory compliance using AI

Global AI Inc. (OTC: GLAI) announced on January 29, 2026. It signed an enterprise contract with a leading global pharmaceutical and life sciences company. The deal will deploy Global AI's enterprise-grade Agentic AI Platform to automate regulatory monitoring, compliance reporting, and HR operations. The platform lets teams design, deploy, and scale AI workflows with governance and compliance built in. It provides end-to-end audit logs across the reporting lifecycle. The platform is designed to meet multi-jurisdictional pharma standards. Darko Horvat is chairman and CEO of Global AI. He said the deployment shows the company's ability to run at enterprise scale in compliance-driven environments. The agreement validates the platform in regulated sectors and could support broader adoption across business units.

Why It Matters

• Automate regulatory monitoring and compliance reporting with traceable AI agents to reduce manual reporting and audit workload.
• Built-in governance and end-to-end audit logs help meet multi-jurisdictional pharma standards without heavy custom integration.
• Validation by a leading pharmaceutical firm supports enterprise risk assessments and speeds pilot-to-production decisions for agentic AI.